Back

Novel antisense therapy targeting microRNA-132 in patients with heart failure

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Cutting-edge clinical investigations in heart failure Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Jorg Taubel

City St George's University of London, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Atrial fibrillation impairs dynamic right ventricular-pulmonary artery coupling and increases lung congestion during exercise in heart failure and preserved ejection fraction
Doctor K. Omote (Sapporo, JP)
Abstract Slides Video
Presentation thumbnail
Cognitive impairment is a determinant of patient response to disease management programs to reduce readmission in heart failure
Doctor Q. Huynh (Hobart, AU)
Abstract Slides Video
Presentation thumbnail
Cardiovascular death risk in mid-range ejection fraction heart failure: insights from cardiopulmonary exercise test
Doctor G. Gallo (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Deep learning for mortality prediction in patients with a de-novo or worsened heart failure
Doctor R. Herman (Aalst, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Cutting-edge clinical investigations in heart failure

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources